Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs

Optimal techniques for DC generation for immunotherapy in cancer are yet to be established. Study aims were to evaluate: (i) DC activation/maturation milieu (TNF-α +/- IFN-α) and its effects on CD8+ hTERT-specific T cell responses to class I epitopes (p540 or p865), (ii) CD8+ hTERT-specific T cell responses elicited by vaccination with class I alone or both class I and II epitope (p766 and p672)-pulsed DCs, prepared without IFN-α, (iii) association between circulating T regulatory cells (Tregs) and clinical responses

Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data

Invasive mould diseases (IMDs) are often encountered in haematologic patients who undergo chemotherapy or who require allogeneic haematopoietic stem cell transplantation (allo-HSCT), and still represent a challenge for physicians. The availability of antifungals with different targets has set the foundation to improve the outcomes of patients with IMDs and also to develop innovative therapeutic approaches. Among these, using combinations of antifungal drugs is an attractive option for reasons such as the broader spectrum of activity, synergy between compounds with different targets, and a reduced risk of fungal resistance. In addition, in vitro studies and animal models have provided evidence supporting the use of combination strategies. Although no controlled, well-powered, prospective clinical trials are yet available to demonstrate the superiority of combination versus monotherapy, the persistently high mortality rate associated with IMDs has stimulated the use of combinations of antifungal drugs, both in adult and paediatric patients. In this paper, we review the recent published literature on combination therapy for the treatment of IMDs in adult and paediatric haematologic patient

Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data

nvasive mould diseases (IMDs) are often encountered in haematologic patients who undergo chemotherapy or who require allogeneic haematopoietic stem cell transplantation (allo-HSCT), and still represent a challenge for physicians. The availability of antifungals with different targets has set the foundation to improve the outcomes of patients with IMDs and also to develop innovative therapeutic approaches. Among these, using combinations of antifungal drugs is an attractive option for reasons such as the broader spectrum of activity, synergy between compounds with different targets, and a reduced risk of fungal resistance. In addition, in vitro studies and animal models have provided evidence supporting the use of combination strategies. Although no controlled, well-powered, prospective clinical trials are yet available to demonstrate the superiority of combination versus monotherapy, the persistently high mortality rate associated with IMDs has stimulated the use of combinations of antifungal drugs, both in adult and paediatric patients. In this paper, we review the recent published literature on combination therapy for the treatment of IMDs in adult and paediatric haematologic patients